The COVID-19 pandemic accelerated the development and adoption of nanomedicines, with mRNA–lipid nanoparticle vaccines demonstrating their potential at an unprecedented scale and driving rapid growth in the field. At the same time, this momentum has highlighted critical gaps in Canada’s capacity to sustain and advance nanomedicine innovation. Training opportunities that integrate engineering, nanotechnology, biology, and regulatory science remain limited, while expertise in nanoparticle stability and characterization, including colloidal, physicochemical, and chemical interactions with biological fluids, remains fragmented across the country. Graduate students working on nanomedicine technologies are often exposed to only a subset of the analytical processes required to support regulatory approval, leaving a gap between academic training and the multidisciplinary expertise required in industry. Meanwhile, emerging technologies such as microfluidics, machine learning, plasmonics, and artificial intelligence remain underutilized in analytical workflows, despite their potential to enhance precision and accelerate the characterization and evaluation of new nanomedicines. ICARE-Nanomed was created to address these challenges by establishing a national, interdisciplinary training network that equips highly qualified personnel with the scientific and technical expertise, regulatory awareness, and strategic perspective needed to translate nanomedicine research into impactful innovations and strengthen Canada’s capacity in this rapidly evolving field.